Update on US Clinical Education Programme

Patients have now been successfully treated using the Speedboat device in the UK, South Africa, Mainland Europe and the US.

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that additional gastrointestinal (GI) surgeons in the US have performed successful treatments in both upper and lower GI cases using Creo’s Speedboat device powered by the Company’s CROMA Advanced Energy platform.

Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist.

This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme.

All of these initial users of Speedboat form part of the Creo’s education led strategy to identify and develop the training centres of the future, not only in the US market but also throughout our distribution network. This considered and targeted approach represents our investment in the future of the business. Speedboat is the first device of a range of GI devices to be cleared for use with the CROMA Advanced Energy platform that uniquely harnesses the use of bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and Specialist in GI Endoscopy at the East Kent University Hospitals Foundation Trust, has been overseeing training to the US surgeons on the techniques required to successfully undertake procedures utilising Speedboat. Speedboat helps to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures, reduces the length of stay in hospital for the patient, and reduces the cost of treatment by transferring therapy from the operating theatre to the endoscopy room.

Patients have now been successfully treated using the Speedboat device in the UK, South Africa, Mainland Europe and the US.

Craig Gulliford, Chief Executive Officer of Creo, commented:

A training-led commercialisation strategy is key to the successful roll-out of our products and we are delighted with the progress that we are making with clinicians in the US. Our Clinical Education Programme ensures that the first adopters of our technology, having been carefully mentored by our own doctors and endoscopy nurses, can deliver consistently high standards in this emerging field of surgical endoscopy, safeguarding quality control and ensuring best patient outcomes.

Posted 28/03/2019

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)

Read

13 May 2024

Directorate Changes - May 2024

Read

07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation

Read

02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital

Read

24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings

Read

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

10 January 2024

First Use of Speedboat® UltraSlim in Latin America

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read